Investors & Media : on Data Provided by Refinitiv. Minimum 15 minutes delayed. Intra 3 mo. 6 mo. 1 yr. News Releases FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH Jan 19, 2023 Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023 Jan 05, 2023 Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023 Jan 04, 2023 Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH Dec 23, 2022 View all press releases > Recent Events and Presentations J.P. Morgan 41st Annual Healthcare Conference Jan 12, 2023 at 12:00 PM PST Download Audio Piper Sandler’s 34th Annual Healthcare Conference Dec 1, 2022 Q3 2022 Intercept Pharmaceuticals Earnings Call Nov 1, 2022 at 8:30 AM EDT H.C. Wainwright’s 6th Annual NASH Investor Conference Oct 17, 2022 at 2:30 PM EDT View all events & presentations >
FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH Jan 19, 2023
Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023 Jan 05, 2023
Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023 Jan 04, 2023
Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH Dec 23, 2022